# Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers

> **NCT02392637** · PHASE2 · COMPLETED · sponsor: **M.D. Anderson Cancer Center** · enrollment: 62 (actual)

## Conditions studied

- Stage III Intrahepatic Cholangiocarcinoma AJCC v7
- Stage IIIA Gallbladder Cancer AJCC v7
- Stage IIIB Gallbladder Cancer AJCC v7
- Stage IVA Gallbladder Cancer AJCC v7
- Stage IVA Intrahepatic Cholangiocarcinoma AJCC v7
- Stage IVB Gallbladder Cancer AJCC v7
- Stage IVB Intrahepatic Cholangiocarcinoma AJCC v7
- Unresectable Extrahepatic Bile Duct Carcinoma
- Unresectable Gallbladder Carcinoma

## Interventions

- **DRUG:** Cisplatin
- **DRUG:** Gemcitabine Hydrochloride
- **OTHER:** Laboratory Biomarker Analysis
- **DRUG:** Nab-paclitaxel

## Key facts

- **NCT ID:** NCT02392637
- **Lead sponsor:** M.D. Anderson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-04-02
- **Primary completion:** 2020-08-13
- **Final completion:** 2020-08-13
- **Target enrollment:** 62 (ACTUAL)
- **Last updated:** 2022-02-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02392637

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02392637, "Gemcitabine Hydrochloride, Cisplatin, and Nab-Paclitaxel in Treating Patients With Advanced or Metastatic Biliary Cancers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02392637. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*